Shanghai Fosun Pharmaceutical falls as Alzheimer drug hits a snag
** Hong Kong shares of Shanghai Fosun Pharmaceutical drop 10.9% to HK$14.42, their lowest level since May 2025
** Shanghai-listed stock 600196.SS fall 8.6% to 20.4 yuan, the lowest point since February 2024
** Company says its unit plans to license an Alzheimer's disease drug from South Korean pharmaceutical firm AriBio Co Ltd this year and will decide whether to exercise an option to formally license the drug once the results of the Phase III clinical trials are available
** Data from Phase III clinical trial of oral drug AR1001 showed that primary endpoint achieved statistical significance in monotherapy group, meeting the primary efficacy objective, but the difference between the treatment group and the placebo group did not reach statistical significance in overall polulation - co
** Company said it will further analyze and evaluate the research data related to AR1001 to determine whether to exercise the option
** YTD, Hong Kong stock down 23.9%, Shanghai-listed shares down 21.3%